169 related articles for article (PubMed ID: 35590284)
1. The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study.
Hansen BÅ; Grude N; Lindbæk M; Stenstad T
BMC Infect Dis; 2022 May; 22(1):478. PubMed ID: 35590284
[TBL] [Abstract][Full Text] [Related]
2. Oral beta-lactam step down in bacteremic E. coli urinary tract infections.
Saad S; Mina N; Lee C; Afra K
BMC Infect Dis; 2020 Oct; 20(1):785. PubMed ID: 33087051
[TBL] [Abstract][Full Text] [Related]
3. Pivmecillinam--therapy of choice for lower urinary tract infection.
Graninger W
Int J Antimicrob Agents; 2003 Oct; 22 Suppl 2():73-8. PubMed ID: 14527775
[TBL] [Abstract][Full Text] [Related]
4. Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source.
Sutton JD; Stevens VW; Chang NN; Khader K; Timbrook TT; Spivak ES
JAMA Netw Open; 2020 Oct; 3(10):e2020166. PubMed ID: 33030555
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Iversen A; Kalin M; Giske CG
Microb Drug Resist; 2012 Apr; 18(2):189-92. PubMed ID: 22204597
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.
Bollestad M; Grude N; Solhaug S; Raffelsberger N; Handal N; Nilsen HS; Romstad MR; Emmert A; Tveten Y; Søraas A; Jenum PA; Jenum S; Møller-Stray J; Weme ET; Lindbaek M; Simonsen GS;
J Antimicrob Chemother; 2018 Sep; 73(9):2503-2509. PubMed ID: 29982514
[TBL] [Abstract][Full Text] [Related]
8. Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women.
Monsen TJ; Holm SE; Ferry BM; Ferry SA
APMIS; 2014 Apr; 122(4):317-23. PubMed ID: 24738161
[TBL] [Abstract][Full Text] [Related]
9. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
[TBL] [Abstract][Full Text] [Related]
10. Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI).
Tverring J; Månsson E; Andrews V; Ljungquist O
Trials; 2023 Sep; 24(1):568. PubMed ID: 37660037
[TBL] [Abstract][Full Text] [Related]
11. Treatment duration of pivmecillinam in men, non-pregnant and pregnant women for community-acquired urinary tract infections caused by Escherichia coli: a retrospective Danish cohort study.
Boel JB; Jansåker F; Hertz FB; Hansen KH; Thønnings S; Frimodt-Møller N; Knudsen JD
J Antimicrob Chemother; 2019 Sep; 74(9):2767-2773. PubMed ID: 31098630
[TBL] [Abstract][Full Text] [Related]
12. Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Syre H; Hetland MAK; Bernhoff E; Bollestad M; Grude N; Simonsen GS; Löhr IH
APMIS; 2020 Mar; 128(3):232-241. PubMed ID: 31755584
[TBL] [Abstract][Full Text] [Related]
13. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
[TBL] [Abstract][Full Text] [Related]
14. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial.
Vik I; Bollestad M; Grude N; Bærheim A; Damsgaard E; Neumark T; Bjerrum L; Cordoba G; Olsen IC; Lindbæk M
PLoS Med; 2018 May; 15(5):e1002569. PubMed ID: 29763434
[TBL] [Abstract][Full Text] [Related]
15. Retrospective evaluation of nitrofurantoin and pivmecillinam for the treatment of lower urinary tract infections in men.
Montelin H; Forsman KJ; Tängdén T
PLoS One; 2019; 14(1):e0211098. PubMed ID: 30682092
[TBL] [Abstract][Full Text] [Related]
16. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
Søraas A; Sundsfjord A; Jørgensen SB; Liestøl K; Jenum PA
PLoS One; 2014; 9(1):e85889. PubMed ID: 24454943
[TBL] [Abstract][Full Text] [Related]
17. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility to mecillinam of Escherichia coli strains isolated from the urine of pregnant women.
Duployez C; Loiez C; Cattoen C; Descamps D; Wallet F; Vachée A;
Med Mal Infect; 2016 Dec; 46(8):436-441. PubMed ID: 27609597
[TBL] [Abstract][Full Text] [Related]
19. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
[TBL] [Abstract][Full Text] [Related]
20. Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women.
Ejrnaes K; Sandvang D; Lundgren B; Ferry S; Holm S; Monsen T; Lundholm R; Frimodt-Moller N
J Clin Microbiol; 2006 May; 44(5):1776-81. PubMed ID: 16672406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
